Human CD38 Protein 4438

$270.00 – $900.00

Summary

Expression: HEK293
Functional: Yes (ELISA)
Amino Acid Range: Val43-Ile300

SKU: 4438parent Categories: proteins, Recombinant proteins Tag: active proteins

Weight	1 lbs
Dimensions	9 × 5 × 2 in
accession	P28907
express system	HEK293
product tag	C-His
purity	> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC
background	CD38 (cluster of differentiation 38), also known as cyclic ADP ribose hydrolase, is a transmembrane glycoprotein found on the surface of some immune cells including plasma cells, activated or immature T and B cells, monocytes, and natural killer cells. CD38 participates in cell adhesion, signal transduction and calcium signaling.
molecular weight	The protein has a predicted MW of 30.7 kDa. Due to glycosylation, the protein migrates to 45-58 kDa based on Tris-Bis PAGE result.
available size	100 µg, 500 µg
endotoxin	Less than 1EU per μg by the LAL method.

Human CD38 Protein 4438

protein

Size and concentration 100, 500µg and lyophilized
Form Lyophilized
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Storage buffer Shipped at ambient temperature.
Purity > 95% as determined by Tris-Bis PAGE

target relevance
CD38 (cluster of differentiation 38), also known as cyclic ADP ribose hydrolase, is a transmembrane glycoprotein found on the surface of some immune cells including plasma cells, activated or immature T and B cells, monocytes, and natural killer cells. CD38 participates in cell adhesion, signal transduction and calcium signaling.
Protein names ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (EC 3.2.2.-) (EC 3.2.2.6) (2'-phospho-ADP-ribosyl cyclase) (2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase) (EC 2.4.99.20) (2'-phospho-cyclic-ADP-ribose transferase) (ADP-ribosyl cyclase 1) (ADPRC 1) (Cyclic ADP-ribose hydrolase 1) (cADPR hydrolase 1) (T10) (CD antigen CD38)
Gene names CD38,CD38
Protein family ADP-ribosyl cyclase family
Mass 34328Da
Function FUNCTION: Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion (PubMed:7961800, PubMed:8253715). Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+) (PubMed:16690024). Has cADPR hydrolase activity (PubMed:7961800, PubMed:8253715). {ECO:0000269\|PubMed:16690024, ECO:0000269\|PubMed:7961800, ECO:0000269\|PubMed:8253715}.
Catalytic activity CATALYTIC ACTIVITY: Reaction=2'-phospho-cyclic ADP-ribose + nicotinate = nicotinate-adenine dinucleotide phosphate; Xref=Rhea:RHEA:38607, ChEBI:CHEBI:32544, ChEBI:CHEBI:75967, ChEBI:CHEBI:75970; Evidence={ECO:0000269\|PubMed:16690024}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38608; Evidence={ECO:0000269\|PubMed:16690024}; PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:38609; Evidence={ECO:0000269\|PubMed:16690024}; CATALYTIC ACTIVITY: Reaction=NAD(+) = cyclic ADP-beta-D-ribose + nicotinamide + H(+); Xref=Rhea:RHEA:38611, ChEBI:CHEBI:15378, ChEBI:CHEBI:17154, ChEBI:CHEBI:57540, ChEBI:CHEBI:73672; Evidence={ECO:0000269\|PubMed:7961800, ECO:0000269\|PubMed:8253715}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38612; Evidence={ECO:0000269\|PubMed:8253715}; CATALYTIC ACTIVITY: Reaction=NAD(+) + H2O = ADP-D-ribose + nicotinamide + H(+); Xref=Rhea:RHEA:16301, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:17154, ChEBI:CHEBI:57540, ChEBI:CHEBI:57967; EC=3.2.2.6; Evidence={ECO:0000269\|PubMed:16690024, ECO:0000269\|PubMed:8253715}; CATALYTIC ACTIVITY: Reaction=cyclic ADP-beta-D-ribose + H2O = ADP-D-ribose; Xref=Rhea:RHEA:38615, ChEBI:CHEBI:15377, ChEBI:CHEBI:57967, ChEBI:CHEBI:73672; Evidence={ECO:0000269\|PubMed:7961800, ECO:0000269\|PubMed:8253715}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38616; Evidence={ECO:0000269\|PubMed:8253715}; CATALYTIC ACTIVITY: Reaction=NADP(+) = 2'-phospho-cyclic ADP-ribose + nicotinamide; Xref=Rhea:RHEA:38603, ChEBI:CHEBI:17154, ChEBI:CHEBI:58349, ChEBI:CHEBI:75970; Evidence={ECO:0000269\|PubMed:16690024}; CATALYTIC ACTIVITY: Reaction=nicotinate + NADP(+) = nicotinate-adenine dinucleotide phosphate + nicotinamide; Xref=Rhea:RHEA:38599, ChEBI:CHEBI:17154, ChEBI:CHEBI:32544, ChEBI:CHEBI:58349, ChEBI:CHEBI:75967; EC=2.4.99.20; Evidence={ECO:0000305\|PubMed:16690024}; PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38600; Evidence={ECO:0000305\|PubMed:16690024};
Subellular location SUBCELLULAR LOCATION: Cell surface {ECO:0000269\|PubMed:2319135}. Membrane {ECO:0000269\|PubMed:8253715}; Single-pass type II membrane protein.
Tissues TISSUE SPECIFICITY: Expressed at high levels in pancreas, liver, kidney, brain, testis, ovary, placenta, malignant lymphoma and neuroblastoma. {ECO:0000269\|PubMed:8253715, ECO:0000269\|PubMed:9074508}.
Structure SUBUNIT: Homodimer. {ECO:0000305\|PubMed:16154090}.
Target Relevance information above includes information from UniProt accession: P28907
The UniProt Consortium

Data

Anti-CD38 Antibody captured on Protein A chip, can bind Human CD38, His Tag with an affinity constant of 0.23µM as determined in a SPR assay (Biacore T200).

Immobilized Human CD38, His Tag at 1µg/ml (100µl/Well) on the plate. Dose response curve for Anti-CD38 Antibody, hFc Tag with the EC50 of 3.7ng/ml determined by ELISA (QC Test).

The purity of Human CD38 is greater than 95% as determined by SEC-HPLC.

Human CD38 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.